Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study [Corrigendum]

Ítems similars

• Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study
  per: Wang, Chen, et al.
  Publicat: (2015)
• Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]
  Publicat: (2014)
• Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD
  per: Buhl R, et al.
  Publicat: (2012-10-01)
• Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD
  per: Buhl, Roland, et al.
  Publicat: (2012)
• Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
  per: Vincken, Walter, et al.
  Publicat: (2014)